Synergy Pharmaceuticals (SGYP) Given Media Impact Score of 0.08
Media headlines about Synergy Pharmaceuticals (NASDAQ:SGYP) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.4876846108676 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Implied Volatility Surging for Synergy Pharmaceuticals (SGYP) Stock Options (zacks.com)
- Zacks: Brokerages Expect Synergy Pharmaceuticals Inc (SGYP) Will Post Earnings of -$0.19 Per Share (americanbankingnews.com)
- Bordering on Key Levels: Synergy Pharmaceuticals Inc. (SGYP), Oclaro, Inc. (OCLR) – Market Movers (financialqz.com)
- Technical data gathered from Synergy Pharmaceuticals Inc. (SGYP) – Wall Street Morning (wallstreetmorning.com)
- Halozyme Therapeutics, Inc. (HALO), Synergy Pharmaceuticals, Inc. (SGYP) – Newburgh Gazette (newburghgazette.com)
Several analysts have issued reports on SGYP shares. HC Wainwright set a $8.00 price target on Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 18th. BTIG Research reissued a “buy” rating and set a $7.00 price target on shares of Synergy Pharmaceuticals in a report on Tuesday, November 14th. BidaskClub raised Synergy Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 22nd. CIBC reissued a “market perform” rating on shares of Synergy Pharmaceuticals in a report on Friday, January 5th. Finally, Citigroup lowered Synergy Pharmaceuticals to a “market perform” rating in a research note on Friday, January 5th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $8.38.
Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. The firm had revenue of $5.01 million during the quarter, compared to analysts’ expectations of $4.53 million. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. equities research analysts predict that Synergy Pharmaceuticals will post -1.03 earnings per share for the current year.
In related news, major shareholder Paulson & Co. Inc. sold 8,750,000 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $2.82, for a total value of $24,675,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.80% of the stock is currently owned by insiders.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.